Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Free Report)’s share price passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.00 and traded as high as $0.0008. Syros Pharmaceuticals shares last traded at $0.0002, with a volume of 6,934 shares.
Syros Pharmaceuticals Stock Down 75.0%
The firm has a market cap of $5,366.40, a price-to-earnings ratio of 0.00 and a beta of 1.31.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, that is pioneering a new class of targeted therapeutics by focusing on the control of gene expression. Founded in 2015 as a spin-out from the Broad Institute, Syros leverages its proprietary gene control platform to identify and drug key noncoding regions of the genome that regulate disease-driving genes. The company’s approach aims to convert previously undruggable gene targets into precise medicines for patients with cancer and rare genetic disorders.
Syros’ lead development candidate, tamibarotene (SY-1425), is an oral, selective RARα agonist being evaluated in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) characterized by RARA dependence.
Recommended Stories
- Five stocks we like better than Syros Pharmaceuticals
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
